On Demand 2016 Sunday General Sessions

You can earn up to 23.25 AMA PRA Category 1 Credit(s). 

This collection covers general sessions from Sunday's program. This includes plenaries, symposia, and workshops. The sessions listed below are included in this package.

  • Immunotherapy Coming of Age
  • Practical Advice for the Diagnosis/Management of Drug Allergy
  • Meeting the Needs of Distinctive Patient Populations: Pregnancy, the Underserved and Adolescents
  • What to Do When Asthma Does Not Respond to Step 3 Treatment
  • Immunoglobulin Replacement for the Allergist: Update on Guidelines
  • W23 - PBL Workshop - Laboratory Evaluation of the Immune System
  • W25 - Difficult Cases in Primary Immune Deficiency
  • W22 - Skin Biopsy of the Allergist: How to Perform and Interpret
  • W26 - Fat Lips and Swollen Throats: What Are the Facts?
  • W21 - Integrative Medicine in the Allergist's Office: Science and in Practice
  • W20 - Diagnostic Testing for Food Allergy: Old and New
  • W16 - Advocacy Council: 2016 Update on Legal/Regulatory Issues (USP, DASH, ICD-10, etc.)
  • W18 - Essentials of Sterile Compounding for the Allergy Practice
  • W19 - Surviving and Optimizing in the World of EHR
  • Antihistamines Should Be Removed From Anaphylaxis Action Plans

Release Date: 12/01/2016
Expiration Date: 11/30/2019

Accreditation

The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 23.25 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Learning Objectives

  • Discuss the early concepts of immunotherapy and how what we currently do is based on the research of Cooke and his colleagues
  • Review current indications for subcutaneous immunotherapy and best practice of allergen immunotherapy
  • Review current indications for sublingual immunotherapy and best practice of allergen immunotherapy
  • Optimize the evaluation of a patient reporting a drug allergy using a focused history
  • Discuss cost effective methods for using skin testing and drug challenge to evaluate patients reporting a drug allergy
  • Understand when cephalosporins can be used safely despite a history of PCN allergy
  • Integrate new strategies and resources into their practice to help patients from at-risk populations such as the inner city and underserved areas
  • Recognize the ways in which pregnancy may affect asthma, rhinitis and anaphylaxis
  • Prepare their adolescent patients with food allergies and asthma to successfully transition to college
  • Recognize the asthma-COPD overlap syndrome and differences between the two separate conditions
  • Discuss which patients would best respond to anticholinergic and phosphodiesterase inhibitor therapy
  • Describe risks and benefits of therapy with bronchial thermoplasty
  • Recognize how basic science and clinical research has identified distinct pathophysiologic endotypes in severe asthma
  • Describe which patients are candidates for therapy with new biologic agents approved for use in asthma
  • Discuss differences in presentation and treatment of children and adults with severe asthma
  • Interactively discuss a patient with recurrent respiratory infections and the appropriate office evaluation
  • Review the rationale for new tests for immunodeficiency
  • Become aware of new therapeutic options for the patient discussed
  • Identify appropriate evaluation of patients with suspected immune deficiency
  • Learn appropriate strategies for managing patients with primary immune deficiencies
  • Perform a skin biopsy with proper technique and tools
  • Recognize possible complications, adverse effects and limitations of skin biopsy
  • Identify various common interpretations of skin biopsy
  • Discuss the workup and treatment approaches to patients with types 1 and 2 hereditary angioedema (HAE)
  • Discuss the pathophysiology, workup and treatment of histamine-mediated urticaria/angioedema and distinguishing features from type 3 HAE
  • Describe practical services that meet this unique need and how they are billed
  • Describe the components of what is needed for a comprehensive assessment of the patient’s body, mind and spirit
  • Discuss challenges/opportunities for identifying referrals to nutritionists, exercise professionals and clinical psychologists/social workers for mindfulness training
  • Select appropriate components to measure in patients with suspected food allergy, focusing on peanut
  • Recommend appropriate treatment based on the results of the component tests
  • Explain why the RUC reviews codes and how its decisions can impact allergy
  • Adapt these new regulatory requirements to their practices
  • Explain why developing alternative payment models is important to allergists; and use Advocacy Council resources
  • Describe requirements of USP 797 and relevant guidelines for allergen extract compounding
  • Demonstrate the technique of sterile compounding required in office-based practice
  • Define best practices for implementing an EHR in the practice
  • Identify the root causes of common issues with EHRs in the practice
  • Describe the role of epinephrine in the management of anaphylaxis
  • Discuss the risks and benefits of having diphenhydramine as treatment option for anaphylaxis
  • Develop an anaphylaxis action plan they deem most appropriate for their practice
Additional information
Disclosure: 

Harold S. Nelson, MD, FACAAI -- Consultant/Advisor: AstraZeneca, Circassia, Merck; Supported/Contracted Research: Circassia

Anne K. Ellis, MD, MSc, FACAAI -- Consultant/Advisor: ALK, Circassia, GlaxoSmithKline, Merck, Novartis, ALK–Abello, IncALK–Abello, Ora, Inc, Ora, Ora, Inc, Teva; Speaker: AstraZeneca, Circassia, Merck, Novartis, Ora, Ora, Inc, Pfizer; Supported/ Contracted Research: Circassia, GlaxoSmithKline, Merck, Novartis, Pfizer; Board Member for profit organization: Pfizer

David A. Khan, MD, FACAAI -- Speaker: Genentech

Eric M. Macy, MD -- Supported/Contracted Research: ALK

Michael Schatz, MD, MS, FACAAI -- Consultant/Advisor: Amgen, Boston Scientific; Supported/Contracted Research: GlaxoSmithKline, MedImmune, Merck

Todd A. Mahr, MD, FACAAI -- Consultant/Advisor: Meda, Teva; Speaker: Aerocrine, AstraZeneca, GlaxoSmithKline, Meda, Merck, Teva; Supported/Contracted Research: AstraZeneca

Stephen Peters, MD, PhD -- Consultant/Advisor: Aerocrine, Array BioPharma, AstraZeneca, Boehringer Ingelheim, Gilead, GlaxoSmithKline, Merck, Novartis, Ono, Sunovion, Teva

Mario Castro, MD, MPH -- Consultant/Advisor: Boston Scientific, Genentech, GlaxoSmithKline, Neostem, Holaira, Teva; Speaker: Boehringer Ingelheim, Boston Scientific, Genentech, Teva; Supported/Contracted Research: Amgen, Boehringer Ingelheim, Genentech, GlaxoSmithKline, Johnson & Johnson, MedImmune, Novartis, Pfizer, Sanofi, Teva, Vectura

Leonard B. Bacharier, MD, FACAAI -- Consultant/Advisor: Boehringer Ingelheim, DBV Technologies, Genentech, Meda, Merck, Novartis, Sanofi, Teva, Vectura; Speaker: AstraZeneca, Boehringer Ingelheim, Merck, Teva

Reynold A. Panettieri, MD -- Consultant/Advisor: AstraZeneca, Genentech, Gilead, Teva; Speaker: AstraZeneca, GlaxoSmithKline, Novartis, Regeneron, Sanofi, Teva; Supported/Contracted Research: Boston Scientific, MedImmune, Teva

Ray S. Davis, MD, FACAAI, Moderator -- Consultant/Advisor: AstraZeneca, Baxter, Genentech, Meda, Merck, Mylan, Sunovion, Teva; Speaker: AstraZeneca, Meda, Merck, Mylan, Teva

Lisa J. Kobrynski, MD, MPH, FACAAI -- Consultant/Advisor: Baxter, CSL Behring; Supported/Contracted Research: Baxter, Grifols

Marcella R. Aquino, MD, FACAAI -- Supported/Contracted Research: Genentech, Merck, Novartis, Roche

William R. Lumry, MD, FACAAI -- Consultant/Advisor: Biocryst, CSL Behring, Dyax, Genentech, Medical Advisory Board–Hereditary Angioedema Association, Roche, Salix, Shire; Speaker: CSL Behring, Dyax, Genentech, Greer, Meda, Medical Advisory Board–Hereditary Angioedema Association, Salix, Shire, Teva; Supported/Contracted Research: ADMA Biologics, Biocryst, CSL Behring, Circassia, Cytos, Dyax, Genentech, Grifols, Kedrion, Mylan, Novartis, Perrigo, Roche, Shire, Teva, Therapure; Board Member for profit organization: Medical Advisory Board–Hereditary Angioedema Association

Richard W. Weber, MD, FACAAI -- Speaker: AstraZeneca, Meda, Merck; Supported/Contracted Research: GlaxoSmithKline, Regeneron

J. Allen Meadows, MD, FACAAI -- Speaker: Meda

Gary Steven, MD, FACAAI -- Consultant/Advisor: AstraZeneca, Meda; Speaker: Aerocrine, AstraZeneca, Boehringer Ingelheim, Greer, Meda, Merck, Stallergenees; Supported/Contracted Research: AstraZeneca, Circassia, Genentech, GlaxoSmithKline, Merck, Mylan, Novartis, Roche, Teva

Todd A. Mahr, MD, FACAAI -- Consultant/Advisor: Meda, Teva; Speaker: Aerocrine, AstraZeneca, GlaxoSmithKline, Meda, Merck, Teva; Supported/Contracted Research: AstraZeneca

John J. Oppenheimer, MD, FACAAI -- Consultant/Advisor: AstraZeneca, Genentech, GlaxoSmithKline, Meda, Mylan, Novartis, Annals of Allergy, ABAI, Up to date, Teva; Supported/ Contracted Research: AstraZeneca, Genentech, MedImmune, Sanofi

Jay M. Portnoy, MD, FACAAI -- Consultant/Advisor: Boehringer Ingelheim; Speaker: Mylan, Thermo Fisher Scientific

The following have no financial relationships to disclose:

Ira Finegold, MD, FACAAI

Bryan L. Martin, DO, FACAAI

Michael R. Nelson, MD, PhD, FACAAI

Gerald B. Lee, MD

Gailen D. Marshall, MD, PhD, FACAAI

Maeve E. O’Connor, MD, FACAAI

Amal H. Assa’ad, MD, FACAAI

David R. Weldon, MD, FACAAI

Morna J. Dorsey, MD, MMS

Sean A. McGhee, MD

Marianne Frieri, MD, PhD, FACAAI

R. Stokes Peebles, MD, FACAAI

Roland Solensky, MD, FACAAI

David R. Stukus, MD, FACAAI

Wanda Phipatanakul, MD, MS, FACAAI

Aleena Banerji, MD

Course summary
Available credit: 
  • 23.25 AMA PRA Category 1 Credit™
  • 23.25 Attendance
  • 4.00 MOC
Course opens: 
11/30/2016
Course expires: 
11/30/2019
Cost:
$0.00
Rating: 
0

Available Credit

  • 23.25 AMA PRA Category 1 Credit™
  • 23.25 Attendance
  • 4.00 MOC

Accreditation Period

Course opens: 
11/30/2016
Course expires: 
11/30/2019

Price

Cost:
$0.00
Please login or create an account to take this course.